Leerink Partnrs Analysts Boost Earnings Estimates for TNGX

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for Tango Therapeutics in a research report issued on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.29) for the quarter, up from their prior forecast of ($0.36). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.11) EPS and FY2027 earnings at ($1.80) EPS.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). The firm had revenue of $5.39 million during the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%.

Separately, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $12.33.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX opened at $1.52 on Thursday. The stock’s 50-day moving average is $1.46 and its 200-day moving average is $2.58. The company has a market cap of $164.32 million, a P/E ratio of -1.29 and a beta of 1.02. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $12.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TNGX. Barclays PLC increased its stake in Tango Therapeutics by 78.3% during the third quarter. Barclays PLC now owns 126,281 shares of the company’s stock valued at $972,000 after acquiring an additional 55,470 shares during the period. Catalina Capital Group LLC acquired a new stake in shares of Tango Therapeutics during the 4th quarter worth approximately $82,000. Congress Asset Management Co. grew its holdings in shares of Tango Therapeutics by 9.0% during the 4th quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock worth $704,000 after purchasing an additional 18,919 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $218,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Tango Therapeutics by 5.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company’s stock valued at $1,586,000 after purchasing an additional 26,192 shares in the last quarter. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.